Cardiovascular Abnormalities  >>  Synagis (palivizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synagis (palivizumab) / SOBI
NCT01006629 / 2014-004527-42: Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Completed
2/3
100
RoW
palivizumab, ABT-315 (MEDI-493), Synagis 15 mg/kg intramuscularly
Abbott
Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease
04/10
07/10

Download Options